1
|
Agusi ER, Schön J, Allendorf V, Eze EA, Asala O, Shittu I, Balkema-Buschmann A, Wernike K, Tekki I, Ofua M, Adefegha O, Olubade O, Ogunmolawa O, Dietze K, Globig A, Hoffmann D, Meseko CA. SARS-CoV and SARS-CoV -2 cross-reactive antibodies in domestic animals and wildlife in Nigeria suggest circulation of sarbecoviruses. One Health 2024; 18:100709. [PMID: 38533194 PMCID: PMC10963646 DOI: 10.1016/j.onehlt.2024.100709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 03/11/2024] [Indexed: 03/28/2024] Open
Abstract
Anthropogenic exposure of domestic animals, as well as wildlife, can result in zoonotic transmission events with known and unknown pathogens including sarbecoviruses. During the COVID-19 pandemic, SARS-CoV-2 infections in animals, most likely resulting from spill-over from humans, have been documented worldwide. However, only limited information is available for Africa. The anthropozoonotic transmission from humans to animals, followed by further inter- and intraspecies propagation may contribute to viral evolution, and thereby subsequently alter the epidemiological patterns of transmission. To shed light on the possible role of domestic animals and wildlife in the ecology and epidemiology of sarbecoviruses in Nigeria, and to analyze the possible circulation of other, undiscovered, but potentially zoonotic sarbecoviruses in animals, we tested 504 serum samples from dogs, rabbits, bats, and pangolins collected between December 2020 and April 2022. The samples were analyzed using an indirect multi-species enzyme-linked immunosorbent assay (ELISA) based on the receptor binding domain (RBD) of SARS-CoV and SARS-CoV -2, respectively. ELISA reactive sera were further analyzed by highly specific virus neutralization test and indirect immunofluorescence assay for confirmation of the presence of antibodies. In this study, we found SARS-CoV reactive antibodies in 16 (11.5%) dogs, 7 (2.97%) rabbits, 2 (7.7%) pangolins and SARS-CoV-2 reactive antibodies in 20 (13.4%) dogs, 6 (2.5%) rabbits and 2 (7.7%) pangolins, respectively. Interestingly, 2 (2.3%) bat samples were positive only for SARS-CoV RBD reactive antibodies. These serological findings of SARS-CoV and/or SARS-CoV-2 infections in both domestic animals and wildlife indicates exposure to sarbecoviruses and requires further One Health-oriented research on the potential reservoir role that different species might play in the ecology and epidemiology of coronaviruses at the human-animal interface.
Collapse
Affiliation(s)
- Ebere R Agusi
- National Veterinary Research Institute, Vom, Nigeria
- University of Nigeria, Nsukka, Nigeria
| | - Jacob Schön
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | - Valerie Allendorf
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | | | | | | | - Anne Balkema-Buschmann
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | - Kerstin Wernike
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | - Ishaya Tekki
- National Veterinary Research Institute, Vom, Nigeria
| | - Mark Ofua
- SaintMarks-Lagos Urban Forest Sanctuary Initiative (LUFASI), Lagos, Nigeria
| | | | | | | | - Klaas Dietze
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | - Anja Globig
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | - Donata Hoffmann
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Isle of Riems, Germany
| | | |
Collapse
|
2
|
Ngomtcho SCH, Akenji BM, Tchio-Nighie KH, Fokam J, Guenou E, Nsa’Amang Eyebe C, Nzegni Kamkoum YJ, Ntale Tchoffo VD, Buh Nkum C, Tchoudjin Paho HC, Ebogo YMS, Nanfak A, Maidadi-Foudi M, Fouda C, Andigema AS, Nsah Bongdze-em L, Nfor BN, Torimiro J, Zoung-Kanyi Bissek AC, Noubom M, Assoumou Okomo MC, Ateudjieu J. SARS-CoV-2 active infection and antibodies amongst health personnel during the outbreak in Cameroon: Strengthening the health system for response to future public health emergencies. PLoS One 2024; 19:e0304477. [PMID: 38820301 PMCID: PMC11142533 DOI: 10.1371/journal.pone.0304477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 05/13/2024] [Indexed: 06/02/2024] Open
Abstract
BACKGROUND Health personnel (HP) are on the frontlines during response to public health emergencies like COVID-19. This risk of exposure suggests the need for safety in responding to any pandemic. Therefore, to ascertain the rate of SARS-CoV-2 infection and immunity, and their determinants amongst HP become relevant. METHODS A cross sectional health facility-based study was carried-out amongst HP in the Centre Region of Cameroon from 1st February to 30th June 2021. Characteristics and access to preventive tools were collected using face-to-face administered questionnaire. Nasopharyngeal swabs and whole blood were collected for PCR, IgG and IgM testing respectively. STATA version 17 software was used for data analysis. Determinants of COVID-19 infection were explored by estimating crude and adjusted Odd Ratio. RESULTS Out of 510 HP reached, 458 were enrolled with mean age of 35 (±10) years. Thirty-four (7.4%) were PCR-positive to SARS-CoV-2 with 73.5% being clinicians versus 9 (26.4%) non-clinicians (p = 0.05). Sero-positivity to SARS-CoV-2 IgG/IgM was 40.2% (184/458), with 84.2% being clinicians versus 29 (15.8%) non-clinicians (p = 0.733). Amongst the 34 HP with PCR-positivity, 16 (47%) had no antibodies, while, 15 (44%) were IgG only. An estimate of HP (43.7%) had at least an evidence of PCR, IgG or IgM contact to COVID-19. Determinants of PCR-positivity was being clinical staff (AOR = 0.29, P = 0.039); and that of IgG/IgM were being non clinical staff (AOR = 0.41, p = 0.018) and regular use of face masks (AOR = 0.44, p = 0.001). HP trained on IPC (24%) were mainly from peripheral level (74.7%, p = 0.002). CONCLUSION Active infections were within the range of pandemic control (<10%). However, around two-fifths of participants have had contact with the virus, indicating that HP remains a population at risk of COVID-19 and other similarly-transmitted epidemic prone diseases, and also an important source of transmission. There is need of vaccine to achieve protectiveness, and optimal response also requires capacity building to improve the health system when challenged by a future pandemic.
Collapse
Affiliation(s)
- Sen Claudine Henriette Ngomtcho
- National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
- Genomic Surveillance Study Group, Ministry of Public Health, Yaoundé, Cameroon
| | | | | | - Joseph Fokam
- Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Etienne Guenou
- National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon
| | - Carolle Nsa’Amang Eyebe
- Department of Biological Sciences, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Douala, Douala, Cameroon
| | - Yvan Junior Nzegni Kamkoum
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
| | - Valdex Derick Ntale Tchoffo
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
| | - Collins Buh Nkum
- M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon
| | | | | | - Aude Nanfak
- M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon
| | - Martin Maidadi-Foudi
- Centre de Recherche en Maladies Emergentes et Re-emergentes (CREMER), Yaoundé, Cameroun
| | - Crescence Fouda
- National Public Health Laboratory, Ministry of Public Health, Yaoundé, Cameroon
| | - Angyiba Serge Andigema
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
| | - Lilian Nsah Bongdze-em
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
| | - Beri Nadin Nfor
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
| | - Judith Torimiro
- Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Anne Cécile Zoung-Kanyi Bissek
- Division for Operational Health Research (DROS), Ministry of Public Health, Yaoundé, Cameroon
- Department of internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
| | - Michel Noubom
- Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Dschang, Dschang, Cameroon
| | | | - Jérôme Ateudjieu
- M.A. SANTE (Meilleur Accès aux Soins de Santé), Yaoundé, Cameroon
- Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
| |
Collapse
|
3
|
Lee EH, Rashid A, Lawal I, Adekanye U, Adamu Y, Godfrey C, Agaba PA, Okeji N, Desai P. Protecting healthcare workers and patients during the COVID-19 pandemic: a comparison of baseline and follow-up infection prevention and control needs in Nigerian military healthcare facilities delivering HIV services. BMC Health Serv Res 2023; 23:1254. [PMID: 37964245 PMCID: PMC10647028 DOI: 10.1186/s12913-023-10289-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Accepted: 11/07/2023] [Indexed: 11/16/2023] Open
Abstract
BACKGROUND Protecting the HIV health workforce is critical for continuity of services for people living with HIV, particularly during a pandemic. Early in the COVID-19 pandemic, the Nigerian Ministry of Defence, in partnership with the US Military HIV Research Program, took steps to improve infection prevention and control (IPC) practices among staff working in select PEPFAR-supported Nigerian military health facilities. METHODS We identified a set of IPC activities a priori for implementation at four Nigerian military hospitals in HIV and related departments in early 2021, including continuous medical masking, physical distancing, placement of additional hand washing stations and hand sanitizers throughout facilities, and training. We fine-tuned planned intervention activities through a baseline needs assessment conducted in December 2020 that covered eight IPC components: 'IPC program structure, funding and leadership engagement'; 'IPC policies, guidelines and standard operating procedures (SOPs)'; 'infrastructure'; 'triage and screening'; 'training, knowledge and practice'; 'personal protective equipment (PPE) materials, availability and adequacy'; 'biosafety and waste management'; and 'monitoring and remediation' prior to implementation. Baseline results were compared with those of a follow up assessment administered in August 2021, following intervention implementation. RESULTS IPC readiness remained high at both baseline and follow-up assessments for 'IPC guidelines, policies, and SOPs' (96.7%). The components 'infrastructure' and 'monitoring and remediation', which needed improvement at baseline, saw modest improvements at follow-up, by 2% and 7.5%, respectively. At follow-up, declines from high scoring at baseline were seen in 'IPC program structure, funding and leadership engagement', 'training, knowledge and practice', and 'biosafety and waste management'. 'PPE materials availability and adequacy' improved to 88.9% at follow-up. Although unidirectional client flow was newly implemented, the score for 'triage and screening' did not change from baseline to follow-up (73%). CONCLUSION Variability in IPC component readiness and across facilities highlights the importance of building resilience and employing a quality improvement approach to IPC that includes regular monitoring, re-assessment and re-training at set intervals. Results can be used to encourage solutions-oriented dialogue between staff and leadership, determine needs and implement action plans to protect staff and people with HIV.
Collapse
Affiliation(s)
- Elizabeth H Lee
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
| | - Ayesha Rashid
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
| | - Ismail Lawal
- US Army Medical Research Directorate - Africa/Nigeria, Walter Reed Army Institute of Research, Abuja, Nigeria
| | - Usman Adekanye
- Nigerian Ministry of Defence - Health Implementation Programme, Abuja, Nigeria
| | - Yakubu Adamu
- US Army Medical Research Directorate - Africa/Nigeria, Walter Reed Army Institute of Research, Abuja, Nigeria
| | - Catherine Godfrey
- Office of the Global AIDS Coordinator, Department of State, US President's Emergency Plan for AIDS Relief, Washington, DC, USA
| | - Patricia A Agaba
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
| | - Nathan Okeji
- Nigerian Ministry of Defence - Health Implementation Programme, Abuja, Nigeria
| | - Priyanka Desai
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
| |
Collapse
|
4
|
Edukugho AA, Etapelong SG, Gidado S, Abbott SL, Hamisu AW, Hassan IA, Mawashi KY, Erbeto TB, Waziri NE, Nguku P, Omotayo B, Adamu US. Innovative strategies developed to mitigate the impact of COVID-19 pandemic on polio surveillance in Nigeria, 2020. Pan Afr Med J 2023; 45:10. [PMID: 38370097 PMCID: PMC10874093 DOI: 10.11604/pamj.supp.2023.45.2.38261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Accepted: 09/07/2023] [Indexed: 02/20/2024] Open
Abstract
Introduction following the spread of the COVID-19 pandemic to Nigeria, the Federal Government of Nigeria restricted human and vehicular movements to curb the spread of the disease. This action had a negative impact on Acute Flaccid Paralysis (AFP) surveillance, with a resultant reduction in the number of AFP cases reported. This paper describes the impact of the COVID-19 pandemic on poliovirus surveillance in Nigeria and the proactive interventions by Nigeria´s polio program to mitigate the impact of COVID-19 on polio surveillance. Methods nine innovative strategies were implemented in all 774 Local Government Areas (LGA) of the 36 states and Federal Capital Territory (FCT) of the country. These strategies were developed by the national surveillance officers and operationalized by sub-national surveillance officers with different strategies starting at different epidemiological weeks from week 14 to 23, 2020. Many of the strategy innovations were technology-based and included: the use of mobile phones to send the AFP case definition and video by WhatsApp or by SMS, the use of state-specific toll-free numbers and Mobile Telephone Network (MTN) (mobile service provider) CallerfeelTM to community informants (CI) who were the main targets of the interventions to increase case detection and reporting. Others included the use of abridged e-surveillance integrated supportive supervision (ISS) checklists, virtual monthly DSNO meetings, and batched AFP stool specimen transportation network. Results compared to the same period in 2019, the cumulative rate of AFP case detection and reporting had gradually declined from 39.1% in January to 16.7% before the commencement of the interventions in week 20, 2020. However, the detection and reporting increased by 57.% from week 20 to week 47 compared to the same period in 2019. This is because with COVID-19, hospital visitation dropped, and the sick remained in the communities, so the CI network was relied on to detect and report AFP cases. The cumulative proportion of AFP cases reported by community informants as of week 47 increased from 13% in 2018 to 21% in 2020. This indicates an increase of 38%. Thirty-five AFP cases were detected and reported using the MTN Caller Feel strategy, while 15 cases were reported through state-specific toll-free numbers. Conclusion the implementation of the innovative strategies was able to mitigate the low AFP case detection and reporting observed at the initial stage of the COVID-19 pandemic. The use of technology facilitated reaching the CI network, which was more instrumental in detecting and reporting the cases.
Collapse
Affiliation(s)
| | | | - Saheed Gidado
- African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria
| | - Samuel Luka Abbott
- African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria
| | | | | | - Kabir Yusuf Mawashi
- National Primary Healthcare Development Authority, Federal Capital Territory (FCT), Abuja, Nigeria
| | | | | | - Patrick Nguku
- African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria
| | - Bolu Omotayo
- Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Usman Said Adamu
- National Primary Healthcare Development Authority, Federal Capital Territory (FCT), Abuja, Nigeria
| |
Collapse
|
5
|
Otshudiema JO, Folefack GLT, Nsio JM, Kakema CH, Minikulu L, Bafuana A, Kosianza JB, Mfumu AK, Nkwembe E, Munyeku-Bazitama Y, Makiala-Mandanda S, Guinko N, Mbuyi G, Tshilumbu JMK, Saidi GN, Umba-di-Masiala MS, Ebondo AK, Mutonj JJ, Kalombo S, Kabeya J, Mawanda TK, Bile FN, Kasereka GK, Mbala-Kingebeni P, Ahuka-Mundeke S, Karamagi HC, Fai KN, Djiguimde AP. Community-based COVID-19 active case finding and rapid response in the Democratic Republic of the Congo: Improving case detection and response. PLoS One 2023; 18:e0278251. [PMID: 37200322 PMCID: PMC10194859 DOI: 10.1371/journal.pone.0278251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 04/25/2023] [Indexed: 05/20/2023] Open
Abstract
A community-based coronavirus disease (COVID-19) active case-finding strategy using an antigen-detecting rapid diagnostic test (Ag-RDT) was implemented in the Democratic Republic of Congo (DRC) to enhance COVID-19 case detection. With this pilot community-based active case finding and response program that was designed as a clinical, prospective testing performance, and implementation study, we aimed to identify insights to improve community diagnosis and rapid response to COVID-19. This pilot study was modeled on the DRC's National COVID-19 Response Plan and the COVID-19 Ag-RDT screening algorithm defined by the World Health Organization (WHO), with case findings implemented in 259 health areas, 39 health zones, and 9 provinces. In each health area, a 7-member interdisciplinary field team tested the close contacts (ring strategy) and applied preventive and control measures to each confirmed case. The COVID-19 testing capacity increased from 0.3 tests per 10,000 inhabitants per week in the first wave to 0.4, 1.6, and 2.2 in the second, third, and fourth waves, respectively. From January to November 2021, this capacity increase contributed to an average of 10.5% of COVID-19 tests in the DRC, with 7,110 positive Ag-RDT results for 40,226 suspected cases and close contacts who were tested (53.6% female, median age: 37 years [interquartile range: 26.0-50.0)]. Overall, 79.7% (n = 32,071) of the participants were symptomatic and 7.6% (n = 3,073) had comorbidities. The Ag-RDT sensitivity and specificity were 55.5% and 99.0%, respectively, based on reverse transcription polymerase chain reaction analysis, and there was substantial agreement between the tests (k = 0.63). Despite its limited sensitivity, the Ag-RDT has improved COVID-19 testing capacity, enabling earlier detection, isolation, and treatment of COVID-19 cases. Our findings support the community testing of suspected cases and asymptomatic close contacts of confirmed cases to reduce disease spread and virus transmission.
Collapse
Affiliation(s)
| | | | - Justus M. Nsio
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Cathy H. Kakema
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Luigino Minikulu
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Aimé Bafuana
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Joel B. Kosianza
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Antoine K. Mfumu
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Edith Nkwembe
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Yannick Munyeku-Bazitama
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Sheila Makiala-Mandanda
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Noé Guinko
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Gisèle Mbuyi
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | | | - Guy N. Saidi
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | | | - Amos K. Ebondo
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Jean-Jacques Mutonj
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Serge Kalombo
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Jad Kabeya
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Taty K. Mawanda
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Faustin N. Bile
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Gaby K. Kasereka
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Placide Mbala-Kingebeni
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka-Mundeke
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Humphrey Cyprian Karamagi
- Data Analytics and Knowledge Management, World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of Congo
| | | | | |
Collapse
|
6
|
Happi AN, Ayinla AO, Ogunsanya OA, Sijuwola AE, Saibu FM, Akano K, George UE, Sopeju AE, Rabinowitz PM, Ojo KK, Barrett LK, Van Voorhis WC, Happi CT. Detection of SARS-CoV-2 in Terrestrial Animals in Southern Nigeria: Potential Cases of Reverse Zoonosis. Viruses 2023; 15:1187. [PMID: 37243273 PMCID: PMC10222409 DOI: 10.3390/v15051187] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 05/13/2023] [Accepted: 05/15/2023] [Indexed: 05/28/2023] Open
Abstract
Since SARS-CoV-2 caused the COVID-19 pandemic, records have suggested the occurrence of reverse zoonosis of pets and farm animals in contact with SARS-CoV-2-positive humans in the Occident. However, there is little information on the spread of the virus among animals in contact with humans in Africa. Therefore, this study aimed to investigate the occurrence of SARS-CoV-2 in various animals in Nigeria. Overall, 791 animals from Ebonyi, Ogun, Ondo, and Oyo States, Nigeria were screened for SARS-CoV-2 using RT-qPCR (n = 364) and IgG ELISA (n = 654). SARS-CoV-2 positivity rates were 45.9% (RT-qPCR) and 1.4% (ELISA). SARS-CoV-2 RNA was detected in almost all animal taxa and sampling locations except Oyo State. SARS-CoV-2 IgGs were detected only in goats from Ebonyi and pigs from Ogun States. Overall, SARS-CoV-2 infectivity rates were higher in 2021 than in 2022. Our study highlights the ability of the virus to infect various animals. It presents the first report of natural SARS-CoV-2 infection in poultry, pigs, domestic ruminants, and lizards. The close human-animal interactions in these settings suggest ongoing reverse zoonosis, highlighting the role of behavioral factors of transmission and the potential for SARS-CoV-2 to spread among animals. These underscore the importance of continuous monitoring to detect and intervene in any eventual upsurge.
Collapse
Affiliation(s)
- Anise N. Happi
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
| | - Akeemat O. Ayinla
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
| | - Olusola A. Ogunsanya
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
| | - Ayotunde E. Sijuwola
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
| | - Femi M. Saibu
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
| | - Kazeem Akano
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
- Department of Biological Sciences, Faculty of Natural Sciences, Redeemer’s University, Ede 23210, Osun State, Nigeria
| | - Uwem E. George
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
- Department of Biological Sciences, Faculty of Natural Sciences, Redeemer’s University, Ede 23210, Osun State, Nigeria
| | - Adebayo E. Sopeju
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
| | - Peter M. Rabinowitz
- Center for One Health Research, Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA 98109, USA;
| | - Kayode K. Ojo
- Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Re-Emerging Infectious Diseases (CERID), University of Washington School of Medicine, Seattle, WA 98109, USA; (K.K.O.); (L.K.B.); (W.C.V.V.)
| | - Lynn K. Barrett
- Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Re-Emerging Infectious Diseases (CERID), University of Washington School of Medicine, Seattle, WA 98109, USA; (K.K.O.); (L.K.B.); (W.C.V.V.)
| | - Wesley C. Van Voorhis
- Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Re-Emerging Infectious Diseases (CERID), University of Washington School of Medicine, Seattle, WA 98109, USA; (K.K.O.); (L.K.B.); (W.C.V.V.)
| | - Christian T. Happi
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer’s University, Ede 23210, Osun State, Nigeria; (A.O.A.); (O.A.O.); (A.E.S.); (F.M.S.); (K.A.); (U.E.G.); (A.E.S.); (C.T.H.)
- Department of Biological Sciences, Faculty of Natural Sciences, Redeemer’s University, Ede 23210, Osun State, Nigeria
| |
Collapse
|
7
|
Prevalence of Malaria and COVID-19 Infection in Akure North Local Government Area of Ondo State, Nigeria. J Parasitol Res 2023; 2023:9529563. [PMID: 36643715 PMCID: PMC9836811 DOI: 10.1155/2023/9529563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 10/09/2022] [Accepted: 11/08/2022] [Indexed: 01/06/2023] Open
Abstract
Introduction The prevalence of malaria and coronavirus disease (COVID-19) is highly devastating and has led to a serious public health challenge worldwide. In order to ensure proper control and elimination, the State Ministry of Health (MoH) Ondo State, Nigeria conducted medical examinations in Iju/Itaogbolu, Igoba, and Ogbese Health centers to identify and confirm cases of COVID-19 and malaria infection. This study provides the outcome of the epidemiological investigation of the prevalence of COVID-19 and malaria in Akure North Local Government Area of Ondo State, Nigeria. Method The study was a hospital-based secondary data analysis comprising of 11,389 and 682 individuals who visited various health centers in Akure North Local Government Area (LGA) for medical examinations on malaria and COVID-19, respectively. The COVID-19 cases were investigated using the fluid sample collected with a nasal swab or a throat swab, or spit of saliva into a tube and confirmed by real-time polymerase chain reaction (RT-PCR). The Plasmodium falciparum histidine-rich protein 2 (PfHRP2) RDT was employed to detect the P.falciparum antigen among participants' blood samples. Results The total prevalence of malaria and COVID-19 were 67.6% and 12.4%, respectively. Meanwhile, the month of September recorded the highest malaria prevalence of 81.8% while the month of April recorded the least malaria prevalence of 56.4%. Similarly, the highest case of COVID-19 (18.8%) was recorded in the month of November while the least case (2.4%) was recorded in the month of April (p < 0.05). The age range of 12-59 months had the highest malaria prevalence of 74.9% while 0-24 days age range recorded the least prevalence of 15.2% (p > 0.05). Apparently, the children were more infected with malaria parasites while adults were more infected with COVID-19. Conclusion Conclusively, malaria and COVID-19 infections were prevalent in the study area. Thus, the people should be enlightened on the deadly risk of malaria and COVID-19 through the health workers, social media, and the community leaders to ensure compliance with appropriate preventive measures.
Collapse
|
8
|
Ozah E, Irekpita E, Alili U, Onuora VC. Prospective cross-sectional study on the knowledge and practice of patients visiting outpatient urology clinic in Nigeria on coronavirus disease. Pan Afr Med J 2022; 43:40. [PMID: 36505022 PMCID: PMC9716966 DOI: 10.11604/pamj.2022.43.40.31864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Accepted: 09/11/2022] [Indexed: 12/15/2022] Open
Abstract
Introduction coronavirus disease is caused by a respiratory virus (severe acute respiratory syndrome coronavirus 2). It has assumed a health burden worldwide; hence it was declared a public health emergency of international concern. The pandemic has affected all health related disciplines; urology practice is not spared. It has also had its toll on socioeconomic life. The study aims to assess the knowledge and practice of patients visiting outpatient urology clinic on coronavirus disease (COVID-19). Methods this is a cross-sectional study conducted to assess the knowledge and practice of patients visiting outpatient urology clinic on COVID-19. All patients aged 18 years and above who consented were included. Association between independent variables (social demographic characteristics) and dependent variables (knowledge and practice) using Fisher´s exact, while predictors of dependent variables were assessed using logistics regression model. Results a total of 154 respondents participated. Majority of respondents (50.0%) were between 60 and 69 years. Male constitute 90.3% of respondent. Majority, 65% of respondent had good knowledge while (80%) adopted good practice towards preventing COVID-19. There was an association between age and practice of preventive measure (p = 0.032). There were no predictors of knowledge and practice of preventive measures towards coronavirus disease amongst the socio-demographic characteristics. Conclusion concerted efforts should be made at educating the populace on knowledge, good practices across socio-demographic groups on COVID-19, particularly at the Hospital. Measures should be in place to develop Tele-health as this would improve response at curtailing coronavirus disease and improve health care.
Collapse
Affiliation(s)
- Ehiremhen Ozah
- Urology Unit, Department of Surgery, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria,,Corresponding author: Ehiremhen Ozah, Urology Unit, Department of Surgery, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
| | - Eshiobo Irekpita
- Urology Unit, Department of Surgery, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria,,Department of Surgery Urology Division Ambrose Alli University, Ekpoma Edo State, Nigeria
| | - Ugochukwu Alili
- Urology Unit, Department of Surgery, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria
| | - Vincent Chukwudi Onuora
- Urology Unit, Department of Surgery, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria,,Department of Surgery Urology Division Ambrose Alli University, Ekpoma Edo State, Nigeria
| |
Collapse
|
9
|
Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S. SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virol J 2022; 19:144. [PMID: 36076271 PMCID: PMC9452867 DOI: 10.1186/s12985-022-01873-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 08/27/2022] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND COVID-19, the coronavirus disease that emerged in December 2019, caused drastic damage worldwide. At the beginning of the pandemic, available data suggested that the infection occurs more frequently in adults than in infants. In this review, we aim to provide an overview of SARS-CoV-2 infection in children before and after B.1.617.2 Delta and B.1.1.529 Omicron variants emergence in terms of prevalence, transmission dynamics, clinical manifestations, complications and risk factors. METHODS Our method is based on the literature search on PubMed, Science Direct and Google Scholar. From January 2020 to July 2022, a total of 229 references, relevant for the purpose of this review, were considered. RESULTS The incidence of SARS-CoV-2 infection in infants was underestimated. Up to the first half of May, most of the infected children presented asymptomatic or mild manifestations. The prevalence of COVID-19 varied from country to another: the highest was reported in the United States (22.5%). COVID-19 can progress and become more severe, especially with the presence of underlying health conditions. It can also progress into Kawasaki or Multisystem Inflammatory Syndrome (MIS) manifestations, as a consequence of exacerbating immune response. With the emergence of the B.1.617.2 Delta and B.1.1.529 Omicron variants, it seems that these variants affect a large proportion of the younger population with the appearance of clinical manifestations similar to those presented by adults with important hospitalization rates. CONCLUSION The pediatric population constitutes a vulnerable group that requires particular attention, especially with the emergence of more virulent variants. The increase of symptomatic SARS-CoV-2 infection and hospitalization rate among children highlights the need to extend vaccination to the pediatric population.
Collapse
Affiliation(s)
- Haifa Khemiri
- Laboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, 13 place Pasteur, BP74 1002 le Belvédère, Tunis, Tunisia
- LR 20 IPT 02 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia
| | - Kaouther Ayouni
- Laboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, 13 place Pasteur, BP74 1002 le Belvédère, Tunis, Tunisia
- LR 20 IPT 02 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia
| | - Henda Triki
- Laboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, 13 place Pasteur, BP74 1002 le Belvédère, Tunis, Tunisia
| | - Sondes Haddad-Boubaker
- Laboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for the EMR, Institut Pasteur de Tunis, University of Tunis El Manar, 13 place Pasteur, BP74 1002 le Belvédère, Tunis, Tunisia.
- LR 20 IPT 02 Laboratory of Virus, Host and Vectors, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.
| |
Collapse
|
10
|
Cyrille TM, Serge SM, Brice TMJ, Alain TNP, Grace N, Joseph F, Achta H, Gisèle N, Julius N, Marcel T, Melissa S, Lucy N, Ronald P, Claire OAM, Walter PYE, Alain EMG, Richard N, Sara E. Clinical presentation of COVID-19 at the time of testing and factors associated with pre-symptomatic cases in Cameroon. IJID REGIONS 2022; 4:33-41. [PMID: 35720960 PMCID: PMC9148624 DOI: 10.1016/j.ijregi.2022.05.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 05/25/2022] [Accepted: 05/26/2022] [Indexed: 05/29/2023]
Abstract
OBJECTIVES To describe the clinical features at time of testing and explore factors associated with SARS-CoV-2 infection and pre-symptomatic cases in Cameroon. METHODS Data was collected on people in Cameroon who participated in COVID-19 testing by real-time reverse transcriptase-polymerase chain reaction between 1 March and 5 October 2020. After descriptive analysis, multivariate logistic regression was used to identify factors associated with SARS-CoV-2 infection and pre-symptomatic cases. RESULTS Of 85 206 test participants, 14 863 (17.4%) were infected with SARS-CoV-2. The median age for cases was 38.4 years (interquartile range 29.6-49.4); 6.1% were aged <19 years, and 6.3% were ≥65 years. Of these cases, 46.5% had at least one symptom/sign with a median time from illness onset to testing of 6 days (interquartile range 3-9). Cough (64.2%), headache (46.5%), fatigue/malaise (46.0%), shortness of breath (30.6%) and myalgia/arthralgia (25.6%) were the most commonly observed symptoms/signs. Pre-symptomatic SARS-CoV-2 infection was associated with age <50 years, being male and absence of comorbidities. CONCLUSION This study provides a comprehensive summary of the early clinical profile of SARS-CoV-2 infection during the first wave of COVID-19 in Cameroon, which was dominated by pre-symptomatic illness. These findings would be helpful for SARS-CoV-2 surveillance and control at a regional level.
Collapse
Affiliation(s)
| | | | | | | | - Ngondi Grace
- Virology Laboratory, Laquintinie Hospital, Douala, Cameroon
| | - Fokam Joseph
- Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon
| | - Hamadou Achta
- Epidemiology and Public Health Service, Pasteur Centre in Cameroon, Yaoundé, Cameroon
| | | | | | - Tongo Marcel
- Emerging and Reemerging Diseases Research Centre, IMPM, Yaoundé, Cameroon
| | - Sander Melissa
- Tuberculosis Reference Laboratory Bamenda, Bamenda, Cameroon
| | - Ndip Lucy
- Laboratory of Emerging Infectious Diseases, University of Buea, Buea, Cameroon
| | - Perraut Ronald
- Pasteur Centre in Cameroon, Annex of Garoua, Garoua, Cameroon
| | | | | | - Etoundi Mballa Georges Alain
- Public Health Emergency Operations Coordination Centre, Yaoundé, Cameroon
- Department for the Control of Disease, Epidemics, and Pandemics, Ministry of Public Health, Yaoundé, Cameroon
| | - Njouom Richard
- Virology Service, Pasteur Centre in Cameroon, Yaoundé, Cameroon
| | - Eyangoh Sara
- Public Health Emergency Operations Coordination Centre, Yaoundé, Cameroon
- Scientific Department, Pasteur Centre in Cameroon, Yaoundé
| |
Collapse
|
11
|
Katowa B, Kalonda A, Mubemba B, Matoba J, Shempela DM, Sikalima J, Kabungo B, Changula K, Chitanga S, Kasonde M, Kapona O, Kapata N, Musonda K, Monze M, Tembo J, Bates M, Zumla A, Sutcliffe CG, Kajihara M, Yamagishi J, Takada A, Sawa H, Chilengi R, Mukonka V, Muleya W, Simulundu E. Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern. Viruses 2022; 14:v14091865. [PMID: 36146671 PMCID: PMC9504048 DOI: 10.3390/v14091865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/15/2022] [Accepted: 08/19/2022] [Indexed: 11/16/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have significantly impacted the global epidemiology of the pandemic. From December 2020 to April 2022, we conducted genomic surveillance of SARS-CoV-2 in the Southern Province of Zambia, a region that shares international borders with Botswana, Namibia, and Zimbabwe and is a major tourist destination. Genetic analysis of 40 SARS-CoV-2 whole genomes revealed the circulation of Alpha (B.1.1.7), Beta (B.1.351), Delta (AY.116), and multiple Omicron subvariants with the BA.1 subvariant being predominant. Whereas Beta, Delta, and Omicron variants were associated with the second, third, and fourth pandemic waves, respectively, the Alpha variant was not associated with any wave in the country. Phylogenetic analysis showed evidence of local transmission and possible multiple introductions of SARS-CoV-2 VOCs in Zambia from different European and African countries. Across the 40 genomes analysed, a total of 292 mutations were observed, including 182 missense mutations, 66 synonymous mutations, 23 deletions, 9 insertions, 1 stop codon, and 11 mutations in the non-coding region. This study stresses the need for the continued monitoring of SARS-CoV-2 circulation in Zambia, particularly in strategically positioned regions such as the Southern Province which could be at increased risk of introduction of novel VOCs.
Collapse
Affiliation(s)
- Ben Katowa
- Macha Research Trust, Choma 20100, Zambia
- Department of Biomedical Sciences, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
| | - Annie Kalonda
- Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka 10101, Zambia
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
- Africa Centre of Excellence for Infectious Diseases of Humans and Animals, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
| | - Benjamin Mubemba
- Department of Wildlife Sciences, School of Natural Resources, Copperbelt University, Kitwe 50100, Zambia
- Department of Biomedical Sciences, School of Medicine, Copperbelt University, Ndola 50100, Zambia
| | | | | | - Jay Sikalima
- Churches Health Association of Zambia, Lusaka 10101, Zambia
| | - Boniface Kabungo
- Southern Provincial Health Office, Ministry of Health, Choma 20100, Zambia
| | - Katendi Changula
- Department of Paraclinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
| | - Simbarashe Chitanga
- Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka 10101, Zambia
- Department of Preclinical Studies, School of Veterinary Medicine, University of Namibia, Windhoek Private Bag 13301, Namibia
- School of Life Sciences, College of Agriculture, Engineering and Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa
| | - Mpanga Kasonde
- Zambia National Public Health Institute, Ministry of Health, Lusaka 10101, Zambia
| | - Otridah Kapona
- Zambia National Public Health Institute, Ministry of Health, Lusaka 10101, Zambia
| | - Nathan Kapata
- Zambia National Public Health Institute, Ministry of Health, Lusaka 10101, Zambia
| | - Kunda Musonda
- Zambia National Public Health Institute, Ministry of Health, Lusaka 10101, Zambia
| | - Mwaka Monze
- Virology Laboratory, University Teaching Hospital, Lusaka 10101, Zambia
| | - John Tembo
- HerpeZ Infection Research and Training, University Teaching Hospital, Lusaka 10101, Zambia
| | - Matthew Bates
- HerpeZ Infection Research and Training, University Teaching Hospital, Lusaka 10101, Zambia
- School of Life and Environmental Sciences, University of Lincoln, Lincoln, Lincolnshire LN6 7TS, UK
| | - Alimuddin Zumla
- Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London NW3 2PF, UK
| | - Catherine G. Sutcliffe
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Masahiro Kajihara
- Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
| | - Junya Yamagishi
- Division of Collaboration and Education, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
- International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
| | - Ayato Takada
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
- Africa Centre of Excellence for Infectious Diseases of Humans and Animals, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
- Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
- International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
- One Health Research Center, Hokkaido University, N18 W9, Kita-ku, Sapporo 001-0020, Japan
| | - Hirofumi Sawa
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
- Africa Centre of Excellence for Infectious Diseases of Humans and Animals, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
- Division of Collaboration and Education, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
- One Health Research Center, Hokkaido University, N18 W9, Kita-ku, Sapporo 001-0020, Japan
- Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, N20 W10, Kita-ku, Sapporo 001-0020, Japan
- Division of International Research Promotion, Hokkaido University International Institute for Zoonosis Control, N20 W10, Kita-ku, Sapporo 001-0020, Japan
- Global Virus Network, 725 W Lombard Street, Baltimore, MD 21201, USA
| | - Roma Chilengi
- Zambia National Public Health Institute, Ministry of Health, Lusaka 10101, Zambia
- Republic of Zambia State House, Lusaka 10101, Zambia
| | - Victor Mukonka
- Zambia National Public Health Institute, Ministry of Health, Lusaka 10101, Zambia
| | - Walter Muleya
- Department of Biomedical Sciences, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
| | - Edgar Simulundu
- Macha Research Trust, Choma 20100, Zambia
- Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
- Correspondence:
| |
Collapse
|
12
|
Ikwuegbuenyi CA, Patil SN, Nie JW, Bankole OB, Mehta AI. Effects of COVID-19 on Neurosurgical Service: Perspective from a Tertiary Medical Center in Nigeria. J Neurosci Rural Pract 2022; 13:398-402. [PMID: 35946013 PMCID: PMC9357510 DOI: 10.1055/s-0042-1744472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Background
The outbreak of COVID-19 caused a significant impact on neurosurgical case volume in Nigeria due to the widespread recommendation to minimize elective procedures and redistribute healthcare resources to support COVID-19 patients. This study aims to analyze the effect of COVID-19 in one tertiary care Nigerian hospital on the demographic characteristics, diagnostic classes, and elective/non-elective procedure statuses.
Methods
A retrospective single-center chart review study was conducted to review all patients undergoing a neurosurgical procedure between March to June in 2019 and 2020. Descriptive data on patient age, gender, sex, diagnosis, surgical procedure, elective/non-elective surgery status, and month and year of admission were recorded. Diagnoses were categorized into one of seven types by author review. Pearson's Chi-Square and Fisher's Exact Tests were utilized to test for independence of the categorical variables to the year of patient admission, and a Welch two-sample t-test was used to test for a significant difference in mean age between the two cohorts.
Results
A total of 143 cases were reviewed. There was a 59.8% reduction in overall neurosurgical case volume with an 82% reduction in elective procedures (39 vs. 7, p = 0.017, 95% CI: 1.15 – 8.77) between 2019 and 2020. No significant differences were noted in patient cohorts when comparing demographic characteristics, diagnosis type, or month of admission between the two years.
Conclusion
There was a significant reduction in elective neurosurgical procedures during the early months of COVID-19 in Nigeria. Further studies should consider examining the effects of COVID-19 into 2021.
Collapse
Affiliation(s)
| | - Shashank N. Patil
- College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States
- Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, United States
| | - James W. Nie
- Department of Neurosurgery, College of Medicine University of Lagos, Lagos, Nigeria
- College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States
| | - Olufemi B. Bankole
- Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, United States
| | - Ankit I. Mehta
- Department of Neurosurgery, College of Medicine University of Lagos, Lagos, Nigeria
- College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States
| |
Collapse
|
13
|
Umeozuru CM, Usman AB, Olorukooba AA, Abdullahi IN, John DJ, Lawal LA, Uwazie CC, Balogun MS. Performance of COVID-19 case-based surveillance system in FCT, Nigeria, March 2020 –January 2021. PLoS One 2022; 17:e0264839. [PMID: 35421123 PMCID: PMC9009682 DOI: 10.1371/journal.pone.0264839] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Accepted: 02/17/2022] [Indexed: 11/19/2022] Open
Abstract
Introduction The emergence of novel SARS-CoV-2 has caused a pandemic of Coronavirus Disease 19 (COVID-19) which has spread exponentially worldwide. A robust surveillance system is essential for correct estimation of the disease burden and containment of the pandemic. We evaluated the performance of COVID-19 case-based surveillance system in FCT, Nigeria and assessed its key attributes. Methods We used a cross-sectional study design, comprising a survey, key informant interview, record review and secondary data analysis. A self-administered, semi-structured questionnaire was administered to key stakeholders to assess the attributes and process of operation of the surveillance system using CDC’s Updated Guidelines for Evaluation of Public Health Surveillance System 2001. Data collected alongside surveillance data from March 2020 to January 2021 were analyzed and summarized using descriptive statistics. Results Out of 69,338 suspected cases, 12,595 tested positive with RT-PCR with a positive predictive value (PPV) of 18%. Healthcare workers were identified as high-risk group with a prevalence of 23.5%. About 82% respondents perceived the system to be simple, 85.5% posited that the system was flexible and easily accommodates changes, 71.4% reported that the system was acceptable and expressed willingness to continue participation. Representativeness of the system was 93%, stability 40%, data quality 56.2% and timeliness 45.5%, estimated result turnaround time (TAT) was suboptimal. Conclusion The system was found to be useful, simple, flexible, sensitive, acceptable, with good representativeness but the stability, data quality and timeliness was poor. The system meets initial surveillance objectives but rapid expansion of sample collection and testing sites, improvement of TAT, sustainable funding, improvement of electronic database, continuous provision of logistics, supplies and additional trainings are needed to address identified weaknesses, optimize the system performance and meet increasing need of case detection in the wake of rapidly spreading pandemic. More risk-group persons should be tested to improve surveillance effectiveness.
Collapse
Affiliation(s)
- Chikodi Modesta Umeozuru
- Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria
- African Field Epidemiology Network (AFENET), Abuja, Nigeria
- * E-mail:
| | | | | | - Idris Nasir Abdullahi
- Department of Medical Laboratory Science, Ahmadu Bello University, Zaria, Kaduna State, Nigeria
| | - Doris Japhet John
- Department of Public Health, Federal Capital Territory Administration, Abuja, Nigeria
| | - Lukman Ademola Lawal
- Department of Public Health, Federal Capital Territory Administration, Abuja, Nigeria
| | - Charles Chukwudi Uwazie
- Nigeria Field Epidemiology and Laboratory Training Program, Abuja, Nigeria
- African Field Epidemiology Network (AFENET), Abuja, Nigeria
| | | |
Collapse
|
14
|
Nkunzimana E, Bizimana JC, Ndoreraho A, Iteka L, Butoyi P, Leopold O, Nyandwi J. Clinical and Epidemiology Characteristics of COVID-19 Cases Detected During Mass Screening Campaign from July to October 2020 in Bujumbura, Burundi. East Afr Health Res J 2022; 6:127-133. [PMID: 36751687 PMCID: PMC9887485 DOI: 10.24248/eahrj.v6i2.689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 11/25/2022] [Indexed: 02/09/2023] Open
Abstract
Background Coronavirus disease of 2019 (COVID-19) is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2 Virus). It was reported for the first time in Wuhan city, Hubei province of China. The first cases of COVID-19 in Burundi were identified on 31st March 2020. Several signs and symptoms, including mainly; fever, dry cough, fatigue, myalgia, and dyspnea are the most prominent characteristics of the disease. The aim of this study was to provide description of the clinical and epidemiological characteristics of COVID-19 cases identified during the mass screening campaign conducted between July and October, 2020 in Burundi. Methods We conducted a retrospective secondary analysis of data of clients to the mass screening campaign in Bujumbura city that was run between July and October 2020. Clients with complete data and tested for COVID-19 with Reverse Transcription Polymerase Chain Reaction (RT-PCR) were included in the study. Epi-Info 7.2.2.6 was used to perform descriptive and analytical statistics and Quantum Geographic Information System (QGIS) was used for cases mapping. Association between positive cases and independent variables such as sex, history of contact with confirmed COVID-19 case was measured using chi-square statistical test at a p-value of .05. Results The study included 20,114 participants. 243 (1.2%) were tested positive for COVID-19. The mean age for confirmed cases was 33 (±15) years. The majority of cases (72.8%) were between 20 and 59 years of age and they were predominantly males (67.9%). 164 (67.5%) were symptomatic and cough was the most frequent symptom observed 109 (66.5%), followed by rhinorrhea 69 (42.1%). Fever was present in only 18 (11.0%) of symptomatic patients. Participants with a history of contact with a COVID-19 confirmed case (aOR=2.2; 95%CI [1.6-3.0]; p-value <.001), were more likely to be positive for COVID-19. Also, those who were coughing (aOR=1.47; 95%CI [1.06-2.05]; p-value=.023) and having sore throat (aOR=2.4; 95%CI [1.1-4.9]; p-value=.02) were more likely to test positive for COVID-19. Conclusion This study revealed that a significant proportion (32.5%) of COVID-19 patients were silent carriers of the virus. Data highlighted that high proportion of cases were among the active age group and contacts with confirmed cases, and noted high proportion of asymptomatic cases at diagnosis. Measures including routine testing of asymptomatic contacts could contribute to tackling corona virus in Burundi.
Collapse
Affiliation(s)
- Edouard Nkunzimana
- Ministry of Public Health and Fight against AIDS, National Public Health Institute, Bujumbura, Burundi,Ministry of Public Health and Fight against AIDS, National Public Health Emergency Operation Centre, Bujumbura, Burundi,Correspondence to Edouard Nkunzimana ()
| | - Jean Claude Bizimana
- Ministry of Public Health and Fight against AIDS, National Public Health Emergency Operation Centre, Bujumbura, Burundi
| | - Adolphe Ndoreraho
- Ministry of Public Health and Fight against AIDS, National Public Health Institute, Bujumbura, Burundi,Ministry of Public Health and Fight against AIDS, National Public Health Emergency Operation Centre, Bujumbura, Burundi
| | - Liesse Iteka
- Ministry of Public Health and Fight against AIDS, National Public Health Emergency Operation Centre, Bujumbura, Burundi
| | - Pascal Butoyi
- Ministry of Public Health and Fight against AIDS, National Public Health Emergency Operation Centre, Bujumbura, Burundi
| | | | - Joseph Nyandwi
- Ministry of Public Health and Fight against AIDS, National Public Health Institute, Bujumbura, Burundi
| |
Collapse
|
15
|
Egbunah UP, Orenuga OO, Adeyemo WL. Risk of exposure of dental personnel to COVID-19 and their compliance with COVID-19 safety guidance for the dental practice. Niger Postgrad Med J 2021; 28:247-254. [PMID: 34850751 DOI: 10.4103/npmj.npmj_599_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background To curb the spread of the coronavirus disease 2019 (COVID-19), several guidelines for dental practice were proposed by dental practice regulating bodies. Assessing the level of compliance to these guidelines by dental personnel will provide an evidence-based report of their adherence to COVID-19 guidance and if improvement on this is required. Aim To assess the risk of exposure of dental personnel to COVID-19 in the dental facility and their level of compliance with COVID-19 guidance for the dental practice. Methodology This was a descriptive cross-sectional study conducted at the Dental Centre of the Lagos University Teaching Hospital, (LUTH) Lagos, Nigeria. Participants were dental personnel (resident doctors/house officers, dental nurses, dental hygienists and dental technologists) at the Dental Centre, LUTH. COVID-19 risk assessment and compliance with COVID-19 dental practice guidance were assessed using a self-administered questionnaire. Results A total of 131 dental personnel aged 29.4 ± 5.16 years participated in this study. High risk of COVID-19 exposure was noted in trainees in conservative dentistry, paediatric dentistry, oral and maxillofacial surgery, and in dental hygienists. Eight dental personnel (6.1%) reported a confirmed diagnosis of COVID-19. Majority of included specialties reported a low (<50%) to moderate (>50%- <80%) level of compliance with the pre-treatment, during treatment and post-treatment guidance. Conclusion Although dental personnel at the Dental Centre, LUTH had a high risk of exposure to COVID-19, they showed low-to-moderate compliance with pre-treatment, during treatment and post-treatment guidance which led to a relatively high incidence of COVID-19 transmission in the dental clinic.
Collapse
Affiliation(s)
- Uchenna P Egbunah
- Department of Oral and Maxillofacial Surgery, Lagos University Teaching Hospital, Lagos, Nigeria
| | - Omolola O Orenuga
- Department of Child Dental Health, College of Medicine, University of Lagos/Lagos University Teaching Hospital, Lagos, Nigeria
| | - Wasiu L Adeyemo
- Department of Oral and Maxillofacial Surgery, Lagos University Teaching Hospital; Department of Oral and Maxillofacial Surgery, College of Medicine, University of Lagos, Idi - Araba, Lagos, Nigeria
| |
Collapse
|
16
|
Kufa T, Jassat W, Cohen C, Tempia S, Masha M, Wolter N, Walaza S, von Gottburg A, Govender NP, Hunt G, Shonhiwa AM, Ebonwu J, Ntshoe G, Maruma W, Bapela P, Ndhlovu N, Mathema H, Modise M, Shuping L, Manana PN, Moore D, Dangor Z, Verwey C, Madhi SA, Saloojee H, Zar HJ, Blumberg L. Epidemiology of SARS-CoV-2 infection and SARS-CoV-2 positive hospital admissions among children in South Africa. Influenza Other Respir Viruses 2021; 16:34-47. [PMID: 34796674 PMCID: PMC9664941 DOI: 10.1111/irv.12916] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Accepted: 09/15/2021] [Indexed: 12/15/2022] Open
Abstract
Introduction We describe epidemiology and outcomes of confirmed SARS‐CoV‐2 infection and positive admissions among children <18 years in South Africa, an upper‐middle income setting with high inequality. Methods Laboratory and hospital COVID‐19 surveillance data, 28 January ‐ 19 September 2020 was used. Testing rates were calculated as number of tested for SARS‐CoV‐2 divided by population at risk; test positivity rates were calculated as positive tests divided by total number of tests. In‐hospital case fatality ratio (CFR) was calculated based on hospitalized positive admissions with outcome data who died in‐hospital and whose death was judged SARS‐CoV‐2 related by attending physician. Findings 315 570 children aged <18 years were tested for SARS‐CoV‐2; representing 8.9% of all 3 548 738 tests and 1.6% of all children in the country. Of children tested, 46 137 (14.6%) were positive. Children made up 2.9% (n = 2007) of all SARS‐CoV‐2 positive admissions to sentinel hospitals. Among children, 47 died (2.6% case‐fatality). In‐hospital deaths were associated with male sex [adjusted odds ratio (aOR) 2.18 (95% confidence intervals [CI] 1.08–4.40)] vs female; age <1 year [aOR 4.11 (95% CI 1.08–15.54)], age 10–14 years [aOR 4.20 (95% CI1.07–16.44)], age 15–17 years [aOR 4.86 (95% 1.28–18.51)] vs age 1–4 years; admission to a public hospital [aOR 5.07(95% 2.01–12.76)] vs private hospital and ≥1 underlying conditions [aOR 12.09 (95% CI 4.19–34.89)] vs none. Conclusions Children with underlying conditions were at greater risk of severe SARS‐CoV‐2 outcomes. Children > 10 years, those in certain provinces and those with underlying conditions should be considered for increased testing and vaccination.
Collapse
Affiliation(s)
- Tendesayi Kufa
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of Public HealthUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Waasila Jassat
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Cheryl Cohen
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of Public HealthUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Stefano Tempia
- School of Public HealthUniversity of the WitwatersrandJohannesburgSouth Africa
- Influenza Division, National Center for Immunization and Respiratory DiseasesUS Centers for Disease Control and PreventionAtlantaGeorgiaUSA
- MassGenicsDuluthGeorgiaUSA
| | - Maureen Masha
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Nicole Wolter
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of PathologyUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Sibongile Walaza
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Anne von Gottburg
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of PathologyUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Nelesh P. Govender
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of PathologyUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Gillian Hunt
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of PathologyUniversity of the WitwatersrandJohannesburgSouth Africa
| | | | - Joy Ebonwu
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Genevie Ntshoe
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of Health Systems and Public Health, Faculty of Health SciencesUniversity of PretoriaPretoriaSouth Africa
| | - Wellington Maruma
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Poncho Bapela
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Nomathamsanqa Ndhlovu
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Hlengani Mathema
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Motshabi Modise
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Liliwe Shuping
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| | - Pinky N. Manana
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
- School of PathologyUniversity of the WitwatersrandJohannesburgSouth Africa
| | - David Moore
- Department of Pediatrics and Child HealthUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Ziyaad Dangor
- Department of Pediatrics and Child HealthUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Charl Verwey
- Department of Pediatrics and Child HealthUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Shabir A. Madhi
- South African Medical Research Council: Vaccines and Infectious Diseases Analytical Research Unit (VIDA), Faculty of Health Science JohannesburgUniversity of the WitwatersrandJohannesburgSouth Africa
- Department of Science/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Science JohannesburgUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Haroon Saloojee
- Department of Pediatrics and Child HealthUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Heather J. Zar
- Dept of Paediatrics and Child Health, Red Cross Children's Hospital, and SA‐MRC Unit on Child and Adolescent HealthUniversity of Cape TownCape TownSouth Africa
| | - Lucille Blumberg
- National Institute for Communicable DiseasesNational Health Laboratory ServicesJohannesburgSouth Africa
| |
Collapse
|
17
|
Akande OW, Elimian KO, Igumbor E, Dunkwu L, Kaduru C, Olopha OO, Ohanu DO, Nwozor L, Agogo E, Aruna O, Balogun MS, Aderinola O, Ahumibe A, Arinze C, Badaru SO, Nwachukwu W, Dada AO, Erameh C, Hamza K, Mohammed TB, Ndodo N, Obiekea C, Ofoegbunam C, Ogunbode O, Ohonsi C, Tobin EA, Yashe R, Adekaiyaoja A, Asuzu MC, Audu RA, Bello MB, Bello SO, Deeni YY, Disu Y, Joseph G, Ezeokafor C, Habib ZG, Ibeh C, Ike IF, Iwara E, Luka-Lawal RK, Namara G, Okwor T, Olajide L, Ilesanmi OO, Omonigho S, Oyiri F, Takpa K, Ugbogulu NU, Ibekwe P, Oladejo J, Ilori E, Ochu CL, Ihekweazu C. Epidemiological comparison of the first and second waves of the COVID-19 pandemic in Nigeria, February 2020-April 2021. BMJ Glob Health 2021; 6:bmjgh-2021-007076. [PMID: 34794956 PMCID: PMC8602923 DOI: 10.1136/bmjgh-2021-007076] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Accepted: 10/24/2021] [Indexed: 12/26/2022] Open
Abstract
Background With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria. Methods We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis System data of the first and second epidemiological waves, which were between 27 February and 24 October 2020, and 25 October 2020 to 3 April 2021, respectively. Descriptive statistical measures including frequencies and percentages, test positivity rate (TPR), cumulative incidence (CI) and case fatality rates (CFRs) were compared. A p value of <0.05 was considered statistically significant. All statistical analyses were carried out in STATA V.13. Results There were 802 143 tests recorded during the study period (362 550 and 439 593 in the first and second waves, respectively). Of these, 66 121 (18.2%) and 91 644 (20.8%) tested positive in the first and second waves, respectively. There was a 21.3% increase in the number of tests conducted in the second wave with TPR increasing by 14.3%. CI during the first and second waves were 30.3/100 000 and 42.0/100 000 respectively. During the second wave, confirmed COVID-19 cases increased among females and people 30 years old or younger and decreased among urban residents and individuals with travel history within 14 days of sample collection (p value <0.001). Most confirmed cases were asymptomatic at diagnosis during both waves: 74.9% in the first wave; 79.7% in the second wave. CFR decreased during the second wave (0.7%) compared with the first wave (1.8%). Conclusion Nigeria experienced a larger but less severe second wave of COVID-19. Continued implementation of public health and social measures is needed to mitigate the resurgence of another wave.
Collapse
Affiliation(s)
- Oluwatosin Wuraola Akande
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria .,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria
| | - Kelly Osezele Elimian
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Department of Global Public Health, Karolinska Institute, Stockholm, Sweden
| | - Ehimario Igumbor
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,School of Public Health, University of the Western Cape, Bellville, South Africa
| | - Lauryn Dunkwu
- Tony Blair Institute for Global Change, Abuja, Federal Capital Territory, Nigeria
| | - Chijioke Kaduru
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,IQVIA, Abuja, Nigeria
| | - Olubunmi Omowunmi Olopha
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria
| | - Dabri Olohije Ohanu
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Lilian Nwozor
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria
| | - Emmanuel Agogo
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Resolve to Save Lives, Abuja, Federal Capital Territory, Nigeria
| | - Olusola Aruna
- International Health Regulations (IHR) Strengthening Project, Global Operations, UK Health Security Agency, London, UK
| | | | - Olaolu Aderinola
- Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Anthony Ahumibe
- Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Chinedu Arinze
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Sikiru Olanrewaju Badaru
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - William Nwachukwu
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | | | - Cyril Erameh
- Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria
| | - Khadeejah Hamza
- Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria
| | - Tarik Benjamin Mohammed
- Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Nnaemeka Ndodo
- Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Celestina Obiekea
- Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Chinenye Ofoegbunam
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Oladipo Ogunbode
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Cornelius Ohonsi
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria
| | | | - Rimamdeyati Yashe
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Afolabi Adekaiyaoja
- Tony Blair Institute for Global Change, Abuja, Federal Capital Territory, Nigeria
| | - Michael C Asuzu
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria
| | - Rosemary Ajuma Audu
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Department of Microbiology, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria
| | - Muhammad Bashir Bello
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Center for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria
| | - Shaibu Oricha Bello
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Department of Pharmacology & Therapeutics, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria
| | - Yusuf Yahaya Deeni
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Department of Microbiology & Biotechnology, Federal University Dutse, Dutse, Jigawa State, Nigeria.,Centre for Environmental and Public Health Research and Development, Kano, Kano State, Nigeria
| | - Yahya Disu
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Gbenga Joseph
- Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Chidiebere Ezeokafor
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria
| | - Zaiyad Garba Habib
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,University of Abuja Teaching Hospital, Gwagwalada, Abuja, Federal Capital Territory, Nigeria
| | - Christian Ibeh
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Department of Community Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
| | | | - Emem Iwara
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Maryland Global Initiatives Corporation, Abuja, Federal Capital Territory, Nigeria
| | - Rejoice Kudirat Luka-Lawal
- Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Geoffrey Namara
- World Health Organization, Abuja, Federal Capital Territory, Nigeria
| | - Tochi Okwor
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria
| | - Lois Olajide
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Oluwafunke Olufemi Ilesanmi
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,World Health Organization, Abuja, Federal Capital Territory, Nigeria
| | - Solomon Omonigho
- Department of Microbiology, University of Benin, Benin, Edo State, Nigeria
| | - Ferdinand Oyiri
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Koubagnine Takpa
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Joint United Nations Programme on AIDS (UNAIDS), Abuja, Federal Capital Territory, Nigeria
| | - Nkem Usha Ugbogulu
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Priscilla Ibekwe
- Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - John Oladejo
- Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Elsie Ilori
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Chinwe Lucia Ochu
- Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.,Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria
| | - Chikwe Ihekweazu
- Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.,Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| |
Collapse
|
18
|
Okoroiwu HU, Ogar CO, Nja GME, Abunimye DA, Ejemot-Nwadiaro RI. COVID-19 in Nigeria: account of epidemiological events, response, management, preventions and lessons learned. Germs 2021; 11:391-402. [PMID: 34722361 DOI: 10.18683/germs.2021.1276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 05/22/2021] [Accepted: 08/28/2021] [Indexed: 12/23/2022]
Abstract
Introduction After the World Health Organization declared COVID-19 a pandemic, a hand full of cases and deaths have been recorded globally, Nigeria inclusive. Methods A retrospective analysis of the COVID-19 weekly disease update report by the Nigeria Centre for Disease Control (NCDC) covering February 29, 2020 (Week 9) and March 28, 2021 (Week 12) was adopted for this study. Data were curated from the NCDC database. Results As of March 28, 2021, Nigeria is the 5th most affected African country and the 77th most affected country globally with 162,593 COVID-19 cases and 2,048 COVID-19 related deaths. COVID-19 has been reported in all 36 States and the Federal Capital Territory. However, Lagos has remained the epicenter of the pandemic accounting for 35.4% of the pandemic in Nigeria while Kogi State is the least affected State (0.003%). The trend showed male predilection while the age bracket 35-39 years was the most affected. The attack rate was found to be 78.8 per 100,000 of the population while the cumulative death per 100,000 of the population was found to be 1.0. The case fatality rate was found to be 1.30. Approximately 1,778,105 COVID-19 tests have been performed while 923,623 doses of vaccine have been administered. Conclusions COVID-19 has been reported in all states in Nigeria as well as the Federal Capital Territory with many of the cases involving males. The case trend showed a bimodal form indicating a second wave occurrence. Nigeria government has initiated some combative measures as well as vaccine initiation.
Collapse
Affiliation(s)
- Henshaw Uchechi Okoroiwu
- Ph.D, MSc, B.MLS, Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, Arthur Jarvis University, Akpabuyo, Nigeria, Hematology Unit, Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, University of Calabar, PMB 1115 Calabar, Nigeria
| | - Christopher Ogar Ogar
- MSc, B.MLS, Hematology Unit, Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, University of Calabar, PMB 1115 Calabar, Nigeria
| | - Glory Mbe Egom Nja
- Ph.D, MPH, B.Sc, PGDE. Department of Public Health, Faculty of Allied Medical Sciences, University of Calabar, PMB 1115 Calabar, Nigeria
| | - Dennis Akongfe Abunimye
- B.MLS, Hematology Unit, Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, University of Calabar, PMB 1115 Calabar, Nigeria
| | - Regina Idu Ejemot-Nwadiaro
- Ph.D, M.Sc, B.Sc, Department of Public Health, Faculty of Allied Medical Sciences, University of Calabar, PMB 1115 Calabar, Nigeria
| |
Collapse
|
19
|
Amuzie CI, Odini F, Kalu KU, Izuka M, Nwamoh U, Emma-Ukaegbu U, Onyike G. COVID-19 vaccine hesitancy among healthcare workers and its socio-demographic determinants in Abia State, Southeastern Nigeria: a cross-sectional study. Pan Afr Med J 2021; 40:10. [PMID: 34650660 PMCID: PMC8490164 DOI: 10.11604/pamj.2021.40.10.29816] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 07/26/2021] [Indexed: 01/09/2023] Open
Abstract
INTRODUCTION healthcare workers are at higher risk of COVID-19 infection with ease of infection transmissibility to coworkers and patients. Vaccine hesitancy rates of 56% and up to 25% have been reported among healthcare workers in US and China respectively. Vaccination is known as the most effective strategy to combat infectious diseases. Acceptance of the COVID-19 vaccine plays a major role in combating the pandemic. This study assessed the sociodemographic factors associated with COVID-19 vaccine hesitancy among healthcare workers in Abia State. METHODS a cross-sectional study among 422 healthcare workers was conducted in Abia State with an online-based questionnaire. The questionnaire extracted information on socio-demographics and willingness to take vaccine uptake. Descriptive statistics was used to calculate frequencies and proportions. Bivariate analysis was used to test the association between the socio-demographic factors and the outcome variable (vaccine hesitancy). Logistic regression was conducted to identify the predictors of COVID-19 vaccine hesitancy. The level of significance was 5%. RESULTS mean age of the respondents was 40.6 ± 9.5 years and 67.1% were females The COVID-19 vaccine hesitancy rate was 50.5% (95%CI: 45.6%-55.3%). Socio-demographic factors included age, marital status, location of practice, profession, and income. Vaccine Hesitancy was predicted significantly by younger age (aOR=9.34, 95%CI:2.01-43.39), marital status (single) (aOR=4.97, 95%CI:1.46-16.97), lower income (aOR=2.84, 95%CI:1.32-6.08), and profession - Doctor (aOR=0.28, 95%CI:0.11-0.70), Nurse (aOR=0.31, 95%CI:0.15-0.64) and other allied health professionals (aOR=0.22, 95%CI:0.10-0.44). CONCLUSION COVID-19 vaccine hesitancy was high among healthcare workers. Significant sociodemographic predictors influence the uptake of the COVID-19 vaccine. We recommend that the Federal and State Ministries of Health conduct awareness campaigns targeting the younger age group, singles, lower income class, and non-clinical staff.
Collapse
Affiliation(s)
- Chidinma Ihuoma Amuzie
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria,Corresponding author: Chidinma Ihuoma Amuzie, Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria.
| | - Franklin Odini
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria
| | - Kalu Ulu Kalu
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria
| | - Michael Izuka
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria
| | - Uche Nwamoh
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria
| | - Uloaku Emma-Ukaegbu
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria
| | - Grace Onyike
- Department of Community Medicine, Federal Medical Centre Umuahia, Abia State, Nigeria
| |
Collapse
|
20
|
Elimian KO, Aderinola O, Gibson J, Myles P, Ochu CL, King C, Okwor T, Gaudenzi G, Olayinka A, Zaiyad HG, Ohonsi C, Ebhodaghe B, Dan-Nwafor C, Nwachukwu W, Abdus-Salam IA, Akande OW, Falodun O, Arinze C, Ezeokafor C, Jafiya A, Ojimba A, Aremu JT, Joseph E, Bowale A, Mutiu B, Saka B, Jinadu A, Hamza K, Ibeh C, Bello S, Asuzu M, Mba N, Oladejo J, Ilori E, Alfvén T, Igumbor E, Ihekweazu C. Assessing the capacity of symptom scores to predict COVID-19 positivity in Nigeria: a national derivation and validation cohort study. BMJ Open 2021; 11:e049699. [PMID: 34479936 PMCID: PMC8421116 DOI: 10.1136/bmjopen-2021-049699] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVES This study aimed to develop and validate a symptom prediction tool for COVID-19 test positivity in Nigeria. DESIGN Predictive modelling study. SETTING All Nigeria States and the Federal Capital Territory. PARTICIPANTS A cohort of 43 221 individuals within the national COVID-19 surveillance dataset from 27 February to 27 August 2020. Complete dataset was randomly split into two equal halves: derivation and validation datasets. Using the derivation dataset (n=21 477), backward multivariable logistic regression approach was used to identify symptoms positively associated with COVID-19 positivity (by real-time PCR) in children (≤17 years), adults (18-64 years) and elderly (≥65 years) patients separately. OUTCOME MEASURES Weighted statistical and clinical scores based on beta regression coefficients and clinicians' judgements, respectively. Using the validation dataset (n=21 744), area under the receiver operating characteristic curve (AUROC) values were used to assess the predictive capacity of individual symptoms, unweighted score and the two weighted scores. RESULTS Overall, 27.6% of children (4415/15 988), 34.6% of adults (9154/26 441) and 40.0% of elderly (317/792) that had been tested were positive for COVID-19. Best individual symptom predictor of COVID-19 positivity was loss of smell in children (AUROC 0.56, 95% CI 0.55 to 0.56), either fever or cough in adults (AUROC 0.57, 95% CI 0.56 to 0.58) and difficulty in breathing in the elderly (AUROC 0.53, 95% CI 0.48 to 0.58) patients. In children, adults and the elderly patients, all scoring approaches showed similar predictive performance. CONCLUSIONS The predictive capacity of various symptom scores for COVID-19 positivity was poor overall. However, the findings could serve as an advocacy tool for more investments in resources for capacity strengthening of molecular testing for COVID-19 in Nigeria.
Collapse
Affiliation(s)
- Kelly Osezele Elimian
- Nigeria Centre for Disease Control, Abuja, Nigeria
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| | | | - Jack Gibson
- Department of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
| | - Puja Myles
- Department of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
| | | | - Carina King
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| | - Tochi Okwor
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Giulia Gaudenzi
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | | | | | | | | - Oluwatosin Wuraola Akande
- Nigeria Centre for Disease Control, Abuja, Nigeria
- Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria
| | | | | | | | | | | | | | - Emmanuel Joseph
- Kaduna State Infectious Disease Control Center Community Medicine, Kaduna, Nigeria
| | | | | | - Babatunde Saka
- Lagos State Government Ministry of Health, Ikeja, Nigeria
| | | | - Khadeejah Hamza
- Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria
| | - Christian Ibeh
- Department of Community Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria
| | - Shaibu Bello
- Department of Medical Education, Usmanu Danfodiyo University, Sokoto, Nigeria
| | - Michael Asuzu
- Department of Community Medicine, University College Hospital, Ibadan, Nigeria
| | - Nwando Mba
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - John Oladejo
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Elsie Ilori
- Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Tobias Alfvén
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| | - Ehimario Igumbor
- Nigeria Centre for Disease Control, Abuja, Nigeria
- School of Public Health, University of the Western Cape, Bellville, South Africa
| | | |
Collapse
|
21
|
Rodriguez Velásquez S, Jacques L, Dalal J, Sestito P, Habibi Z, Venkatasubramanian A, Nguimbis B, Mesa SB, Chimbetete C, Keiser O, Impouma B, Mboussou F, William GS, Ngoy N, Talisuna A, Gueye AS, Hofer CB, Cabore JW. The toll of COVID-19 on African children: A descriptive analysis on COVID-19-related morbidity and mortality among the pediatric population in Sub-Saharan Africa. Int J Infect Dis 2021; 110:457-465. [PMID: 34332088 PMCID: PMC8457828 DOI: 10.1016/j.ijid.2021.07.060] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 07/21/2021] [Accepted: 07/24/2021] [Indexed: 12/23/2022] Open
Abstract
Introduction Few data on the COVID-19 epidemiological characteristics among the pediatric population in Africa exists. This paper examines the age and sex distribution of the morbidity and mortality rate in children with COVID-19 and compares it to the adult population in 15 Sub-Saharan African countries. Methods A merge line listing dataset shared by countries within the Regional Office for Africa was analyzed. Patients diagnosed within 1 March and 1 September 2020 with a confirmed positive RT-PCR test for SARS-CoV-2 were analyzed. Children's data were stratified into three age groups: 0-4 years, 5-11 years, and 12-17 years, while adults were combined. The cumulative incidence of cases, its medians, and 95% confidence intervals were calculated. Results 9% of the total confirmed cases and 2.4% of the reported deaths were pediatric cases. The 12-17 age group in all 15 countries showed the highest cumulative incidence proportion in children. Adults had a higher case incidence per 100,000 people than children. Conclusion The cases and deaths within the children's population were smaller than the adult population. These differences may reflect biases in COVID-19 testing protocols and reporting implemented by countries, highlighting the need for more extensive investigation and focus on the effects of COVID-19 in children.
Collapse
Affiliation(s)
| | - Léa Jacques
- Institute of Global Health, University of Geneva, 9 chemin des Mines, 1202 Geneva, Switzerland.
| | - Jyoti Dalal
- International Labour Organization, United Nations, C/O Ochsner & Associés, Place de Longemalle 1, 1204 Geneva, Switzerland.
| | - Paolo Sestito
- Institute of Global Health, University of Geneva, 9 chemin des Mines, 1202 Geneva, Switzerland.
| | - Zahra Habibi
- Institute of Global Health, University of Geneva, 9 chemin des Mines, 1202 Geneva, Switzerland
| | - Akarsh Venkatasubramanian
- International Labour Organization, United Nations, C/O Ochsner & Associés, Place de Longemalle 1, 1204 Geneva, Switzerland.
| | - Benedict Nguimbis
- ASP/ GRAPH Network, C/O Ochsner & Associés, Place de Longemalle 1, 1204 Geneva, Switzerland.
| | - Sara Botero Mesa
- Institute of Global Health, University of Geneva, 9 chemin des Mines, 1202 Geneva, Switzerland.
| | | | - Olivia Keiser
- Institute of Global Health, University of Geneva, 9 chemin des Mines, 1202 Geneva, Switzerland.
| | - Benido Impouma
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| | - Franck Mboussou
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| | - George Sie William
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| | - Nsenga Ngoy
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| | - Ambrose Talisuna
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| | - Abdou Salam Gueye
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| | - Cristina Barroso Hofer
- Department of Infectious Diseases, Universidade Federal do Rio de Janeiro, R Bruno Lobo, 50 Ilha do Fundão, Rio de Janeiro, Brazil.
| | - Joseph Waogodo Cabore
- WHO Regional Office for Africa, Epidemic Preparedness and Response Programme, Cité du Djoué, P.O. Box 06, Brazzaville, Republic du Congo.
| |
Collapse
|
22
|
Ogoina D, James HI, Ogoinja SZ. Post-Discharge Symptoms among Hospitalized COVID-19 Patients in Nigeria: A Single-Center Study. Am J Trop Med Hyg 2021; 105:731-736. [PMID: 34270448 PMCID: PMC8592373 DOI: 10.4269/ajtmh.21-0509] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 06/14/2021] [Indexed: 01/09/2023] Open
Abstract
There is a paucity of studies on post-acute COVID-19 syndrome (PCS) among hospitalized COVID-19 survivors from Nigeria. We describe the frequency, types, and duration of post-discharge symptoms suggestive of PCS among previously hospitalized COVID-19 patients in a treatment center in Nigeria. We conducted a retrospective review of admission and post-discharge follow-up medical records of COVID-19 survivors admitted between April and December 2020. A standardized checklist was used to document post-discharge symptoms. PCS was defined as persisting or new post-discharge symptoms lasting at least 3 weeks after initial COVID-19 symptoms. The relationship between study variables and development of PCS was ascertained by univariate analysis. Thirty of 51 previously hospitalized COVID-19 patients (median age, 46 years; male, 66.7%) were studied. Seventeen (56.7%) of the 30 patients developed features suggestive of PCS. Approximately three post-discharge symptoms were reported per patient over a follow-up period of ranging from 3 weeks to 9 months after initial COVID-19 symptoms. Cough, fatigue, and dyspnea were the most common post-discharge symptoms reported. A few patients had symptoms suggestive of thrombosis and COVID-19 reinfection. Among all study variables, baseline COVID-19 severity was the only significant variable associated with the development of PCS. PCS is common in our setting and is characterized by multisystemic signs and symptoms that require vigilance by clinicians for appropriate diagnosis and treatment. Long-term multicenter prospective studies are needed to characterize fully the burden of PCS among COVID-19 survivors in Nigeria.
Collapse
Affiliation(s)
- Dimie Ogoina
- 1Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa State, Nigeria
| | - Hendris Izibewule James
- 1Department of Internal Medicine, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa State, Nigeria
| | - Stanley Zikeyi Ogoinja
- 2Department of Radiology, Niger Delta University Teaching Hospital, Okolobiri, Bayelsa State, Nigeria
| |
Collapse
|
23
|
Randremanana RV, Andriamandimby S, Rakotondramanga JM, Razanajatovo NH, Mangahasimbola RT, Randriambolamanantsoa TH, Ranaivoson HC, Rabemananjara HA, Razanajatovo I, Razafindratsimandresy R, Rabarison JH, Brook CE, Rakotomanana F, Rabetombosoa RM, Razafimanjato H, Ahyong V, Raharinosy V, Raharimanga V, Raharinantoanina SJ, Randrianarisoa MM, Bernardson B, Randrianasolo L, Randriamampionona LBN, Tato CM, DeRisi JL, Dussart P, Vololoniaina MC, Randriatsarafara FM, Randriamanantany ZA, Heraud J. The COVID-19 epidemic in Madagascar: clinical description and laboratory results of the first wave, march-september 2020. Influenza Other Respir Viruses 2021; 15:457-468. [PMID: 33586912 PMCID: PMC8013501 DOI: 10.1111/irv.12845] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 01/25/2021] [Accepted: 01/29/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Following the first detection of SARS-CoV-2 in passengers arriving from Europe on 19 March 2020, Madagascar took several mitigation measures to limit the spread of the virus in the country. METHODS Nasopharyngeal and/or oropharyngeal swabs were collected from travellers to Madagascar, suspected SARS-CoV-2 cases and contact of confirmed cases. Swabs were tested at the national reference laboratory using real-time RT-PCR. Data collected from patients were entered in an electronic database for subsequent statistical analysis. All distribution of laboratory-confirmed cases were mapped, and six genomes of viruses were fully sequenced. RESULTS Overall, 26,415 individuals were tested for SARS-CoV-2 between 18 March and 18 September 2020, of whom 21.0% (5,553/26,145) returned positive. Among laboratory-confirmed SARS-CoV-2-positive patients, the median age was 39 years (IQR: 28-52), and 56.6% (3,311/5,553) were asymptomatic at the time of sampling. The probability of testing positive increased with age with the highest adjusted odds ratio of 2.2 [95% CI: 1.9-2.5] for individuals aged 49 years and more. Viral strains sequenced belong to clades 19A, 20A and 20B indicative of several independent introduction of viruses. CONCLUSIONS Our study describes the first wave of the COVID-19 in Madagascar. Despite early strategies in place Madagascar could not avoid the introduction and spread of the virus. More studies are needed to estimate the true burden of disease and make public health recommendations for a better preparation to another wave.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Fanjasoa Rakotomanana
- Epidemiology and Clinical Research UnitInstitut Pasteur de MadagascarAntananarivoMadagascar
| | | | | | | | | | - Vaomalala Raharimanga
- Epidemiology and Clinical Research UnitInstitut Pasteur de MadagascarAntananarivoMadagascar
| | | | | | - Barivola Bernardson
- Epidemiology and Clinical Research UnitInstitut Pasteur de MadagascarAntananarivoMadagascar
| | - Laurence Randrianasolo
- Epidemiology and Clinical Research UnitInstitut Pasteur de MadagascarAntananarivoMadagascar
| | | | | | | | - Philippe Dussart
- Virology UnitInstitut Pasteur de MadagascarAntananarivoMadagascar
| | | | | | | | - Jean‐Michel Heraud
- Virology UnitInstitut Pasteur de MadagascarAntananarivoMadagascar
- Present address:
Virology DepartmentInstitut Pasteur de DakarDakarSenegal
| |
Collapse
|
24
|
Buowari D, Ogundipe H. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) INFECTION: AN EPIDEMIOLOGICAL REVIEW. Ann Ib Postgrad Med 2021; 19:S68-S76. [PMID: 35095373 PMCID: PMC8791400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND New strains of different organisms, three of which has been caused by betacorona viruses (SARS-CoV, MERS-CoV and SARSCoV- 2) have caused epidemics and pandemics. The COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) started in China in December 2019 has spread globally. Understanding its pattern of spread and how it affects the populace helps to guide formulation of strategies at curbing its spread, managing the disease and allocation of limited resources in tackling the pandemic. METHODOLOGY This is a review article about the epidemiology of the coronavirus disease -2019 (COVID-19). Various search engines were used to accumulate literature on the topic; these include PubMed, Google scholar, Ajol. RESULTS As at October 29, 2020, SARS-CoV2 has spread to all continents except the Antarctica. Though a zoonotic disease, human to human transmission has resulted to this pandemic is via direct and indirect contact of droplets with mucosal surfaces. Most severe cases occur among the elderly, males, and people with co-morbid diseases. The average incubation period is 2-10 days. When compared with SARS-CoV (Ro: 2.3-3.7, mortality rate 11%) and MERS-CoV (Ro: 0.8-1.3, mortality rate: 34.3%), SARS-Cov-2 is a highly infective (Ro: as high as 6.5) with low mortality rates (average range mortality rates 1.83- 6.3%). CONCLUSION COVID-19 is a highly infective novel virus. Older persons and people with medical comorbidities are more susceptible to the severe form of the disease and mortality. As the second wave comes on, a sustainable measure of limiting the spread and consequences of COVID-19 should be more emphasized.
Collapse
Affiliation(s)
- D.Y. Buowari
- Department of Accident and Emergency, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria
| | - H.D. Ogundipe
- Department of Accident and Emergency, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria
| |
Collapse
|
25
|
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Owen RC, Rahim HFA, Al Abdulla SA, Al Kuwari MG, Kandy MC, Saeb H, Ahmed SNN, Al Romaihi HE, Bansal D, Dalton L, Al-Thani MH, Bertollini R. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci Rep 2021; 11:6233. [PMID: 33737535 PMCID: PMC7973743 DOI: 10.1038/s41598-021-85428-7] [Citation(s) in RCA: 62] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 02/26/2021] [Indexed: 01/08/2023] Open
Abstract
The overarching objective of this study was to provide the descriptive epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a series of national epidemiologic studies. Sources of data were the centralized and standardized national databases for SARS-CoV-2 infection. By July 10, 2020, 397,577 individuals had been tested for SARS-CoV-2 using polymerase-chain-reaction (PCR), of whom 110,986 were positive, a positivity cumulative rate of 27.9% (95% CI 27.8-28.1%). As of July 5, case severity rate, based on World Health Organization (WHO) severity classification, was 3.4% and case fatality rate was 1.4 per 1,000 persons. Age was by far the strongest predictor of severe, critical, or fatal infection. PCR positivity of nasopharyngeal/oropharyngeal swabs in a national community survey (May 6-7) including 1,307 participants was 14.9% (95% CI 11.5-19.0%); 58.5% of those testing positive were asymptomatic. Across 448 ad-hoc testing campaigns in workplaces and residential areas including 26,715 individuals, pooled mean PCR positivity was 15.6% (95% CI 13.7-17.7%). SARS-CoV-2 antibody prevalence was 24.0% (95% CI 23.3-24.6%) in 32,970 residual clinical blood specimens. Antibody prevalence was only 47.3% (95% CI 46.2-48.5%) in those who had at least one PCR positive result, but 91.3% (95% CI 89.5-92.9%) among those who were PCR positive > 3 weeks before serology testing. Qatar has experienced a large SARS-CoV-2 epidemic that is rapidly declining, apparently due to growing immunity levels in the population.
Collapse
Affiliation(s)
- Laith J Abu-Raddad
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar.
- World Health Organization Collaborating Centre for Disease Epidemiology Analytics On HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.
- Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
| | - Hiam Chemaitelly
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar
- World Health Organization Collaborating Centre for Disease Epidemiology Analytics On HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar
| | - Houssein H Ayoub
- Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Hatoun Saeb
- Primary Health Care Corporation, Doha, Qatar
| | | | | | | | | | | | | |
Collapse
|
26
|
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Al Kanaani Z, Al Khal A, Al Kuwari E, Butt AA, Coyle P, Jeremijenko A, Kaleeckal AH, Latif AN, Owen RC, Rahim HFA, Al Abdulla SA, Al Kuwari MG, Kandy MC, Saeb H, Ahmed SNN, Al Romaihi HE, Bansal D, Dalton L, Al-Thani MH, Bertollini R. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci Rep 2021; 11:6233. [PMID: 33737535 DOI: 10.1101/2020.07.16.20155317] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 02/26/2021] [Indexed: 05/23/2023] Open
Abstract
The overarching objective of this study was to provide the descriptive epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a series of national epidemiologic studies. Sources of data were the centralized and standardized national databases for SARS-CoV-2 infection. By July 10, 2020, 397,577 individuals had been tested for SARS-CoV-2 using polymerase-chain-reaction (PCR), of whom 110,986 were positive, a positivity cumulative rate of 27.9% (95% CI 27.8-28.1%). As of July 5, case severity rate, based on World Health Organization (WHO) severity classification, was 3.4% and case fatality rate was 1.4 per 1,000 persons. Age was by far the strongest predictor of severe, critical, or fatal infection. PCR positivity of nasopharyngeal/oropharyngeal swabs in a national community survey (May 6-7) including 1,307 participants was 14.9% (95% CI 11.5-19.0%); 58.5% of those testing positive were asymptomatic. Across 448 ad-hoc testing campaigns in workplaces and residential areas including 26,715 individuals, pooled mean PCR positivity was 15.6% (95% CI 13.7-17.7%). SARS-CoV-2 antibody prevalence was 24.0% (95% CI 23.3-24.6%) in 32,970 residual clinical blood specimens. Antibody prevalence was only 47.3% (95% CI 46.2-48.5%) in those who had at least one PCR positive result, but 91.3% (95% CI 89.5-92.9%) among those who were PCR positive > 3 weeks before serology testing. Qatar has experienced a large SARS-CoV-2 epidemic that is rapidly declining, apparently due to growing immunity levels in the population.
Collapse
Affiliation(s)
- Laith J Abu-Raddad
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar.
- World Health Organization Collaborating Centre for Disease Epidemiology Analytics On HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.
- Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
| | - Hiam Chemaitelly
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar
- World Health Organization Collaborating Centre for Disease Epidemiology Analytics On HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar
| | - Houssein H Ayoub
- Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Hatoun Saeb
- Primary Health Care Corporation, Doha, Qatar
| | | | | | | | | | | | | |
Collapse
|
27
|
Abubakar I, Dalglish SL, Ihekweazu CA, Bolu O, Aliyu SH. Lessons from co-production of evidence and policy in Nigeria's COVID-19 response. BMJ Glob Health 2021; 6:e004793. [PMID: 33741561 PMCID: PMC7985933 DOI: 10.1136/bmjgh-2020-004793] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/18/2021] [Accepted: 01/20/2021] [Indexed: 01/08/2023] Open
Abstract
In February 2020, Nigeria faced a potentially catastrophic COVID-19 outbreak due to multiple introductions, high population density in urban slums, prevalence of other infectious diseases and poor health infrastructure. As in other countries, Nigerian policymakers had to make rapid and consequential decisions with limited understanding of transmission dynamics and the efficacy of available control measures. We present an account of the Nigerian COVID-19 response based on co-production of evidence between political decision-makers, health policymakers and academics from Nigerian and foreign institutions, an approach that allowed a multidisciplinary group to collaborate on issues arising in real time. Key aspects of the process were the central role of policymakers in determining priority areas and the coordination of multiple, sometime conflicting inputs from stakeholders to write briefing papers and inform effective national decision making. However, the co-production approach met with some challenges, including limited transparency, bureaucratic obstacles and an overly epidemiological focus on numbers of cases and deaths, arguably to the detriment of addressing social and economic effects of response measures. Larger systemic obstacles included a complex multitiered health system, fragmented decision-making structures and limited funding for implementation. Going forward, Nigeria should strengthen the integration of the national response within existing health decision bodies and implement strategies to mitigate the social and economic impact, particularly on the poorest Nigerians. The co-production of evidence examining the broader public health impact, with synthesis by multidisciplinary teams, is essential to meeting the social and public health challenges posed by the COVID-19 pandemic in Nigeria and other countries.
Collapse
Affiliation(s)
- Ibrahim Abubakar
- Institute for Global Health, University College London, London, UK
| | - Sarah L Dalglish
- Institute for Global Health, University College London, London, UK
| | - Chikwe A Ihekweazu
- Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
| | - Omotayo Bolu
- U.S. Centers for Disease Control and Prevention, Nigeria Country Office, Abuja, Nigeria
| | - Sani H Aliyu
- Nigerian Presidential Taskforce on COVID-19, Abuja, Nigeria
| |
Collapse
|
28
|
Olumade TJ, Uzairue LI. Clinical characteristics of 4499 COVID-19 patients in Africa: A meta-analysis. J Med Virol 2021; 93:3055-3061. [PMID: 33543800 PMCID: PMC8013423 DOI: 10.1002/jmv.26848] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 01/19/2021] [Accepted: 01/31/2021] [Indexed: 01/08/2023]
Abstract
The novel coronavirus disease‐2019 (COVID‐19) pandemic that started in December 2019 has affected over 95 million people and killed over 2 million people as of January 19, 2021. While more studies are published to help us understand the virus, there is a dearth of studies on the clinical characteristics and associated outcomes of the severe acute respiratory syndrome coronavirus 2 on the African continent. We evaluated evidence from previous studies in Africa available in six databases between January 1 and October 6, 2020. Meta‐analysis was then performed using Open‐Meta Analyst and Jamovi software. A total of seven studies, including 4499 COVID‐19 patients, were included. The result of the meta‐analysis showed that 68.8% of infected patients were male. Common symptoms presented (with their incidences) were fever (42.8%), cough (33.3%), headache (11.3%), and breathing problems (16.8%). Other minor occurring symptoms included diarrhea (7.5%) and rhinorrhea (9.4%). Fatality rate was 5.6%. There was no publication bias in the study. This study presents the first description and analysis of the clinical characteristics of COVID‐19 patients in Africa. The most common symptoms are fever, cough, and breathing problems.
Collapse
Affiliation(s)
- Testimony Jesupamilerin Olumade
- Department of Biological Sciences, Redeemer's University, Ede, Osun, Nigeria.,African Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun, Nigeria
| | - Leonard Ighodalo Uzairue
- Department of Microbiology, College of Biosciences, Federal University of Agriculture, Abeokuta, Ogun, Nigeria.,Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, Federal University, Oye-Ekiti, Ekiti, Nigeria
| |
Collapse
|
29
|
Elimian KO, Ochu CL, Ebhodaghe B, Myles P, Crawford EE, Igumbor E, Ukponu W, Olayinka A, Aruna O, Dan-Nwafor C, Olawepo OA, Ogunbode O, Atteh R, Nwachukwu W, Venkatesan S, Obagha C, Ngishe S, Suleiman K, Usman M, Yusuff HA, Nwadiuto I, Mohammed AA, Usman R, Mba N, Aderinola O, Ilori E, Oladejo J, Abubakar I, Ihekweazu C. Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: retrospective cohort study. BMJ Open 2020; 10:e044079. [PMID: 33334842 PMCID: PMC7747485 DOI: 10.1136/bmjopen-2020-044079] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 11/05/2020] [Accepted: 11/10/2020] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVE Despite the increasing disease burden, there is a dearth of context-specific evidence on the risk factors for COVID-19 positivity and subsequent death in Nigeria. Thus, the study objective was to identify context-specific factors associated with testing positive for COVID-19 and fatality in Nigeria. DESIGN Retrospective cohort study. SETTING COVID-19 surveillance and laboratory centres in 36 states and the Federal Capital Territory reporting data to the Nigeria Centre for Disease Control. PARTICIPANTS Individuals who were investigated for SARS-CoV-2 using real-time PCR testing during the study period 27 February-8 June 2020. METHODS COVID-19 positivity and subsequent mortality. Multivariable logistic regression analyses were performed to identify factors independently associated with both outcome variables, and findings are presented as adjusted ORs (aORs) and 95% CIs. RESULTS A total of 36 496 patients were tested for COVID-19, with 10 517 confirmed cases. Of 3215 confirmed cases with available clinical outcomes, 295 died. Factors independently associated with COVID-19 positivity were older age (p value for trend<0.0001), male sex (aOR 1.11, 95% CI 1.04 to 1.18) and the following presenting symptoms: cough (aOR 1.23, 95% CI 1.13 to 1.32), fever (aOR 1.45, 95% CI 1.45 to 1.71), loss of smell (aOR 7.78, 95% CI 5.19 to 11.66) and loss of taste (aOR 2.50, 95% CI 1.60 to 3.90). An increased risk of mortality following COVID-19 was observed in those aged ≥51 years, patients in farming occupation (aOR 7.56, 95% CI 1.70 to 33.53) and those presenting with cough (aOR 2.06, 95% CI 1.41 to 3.01), breathing difficulties (aOR 5.68, 95% CI 3.77 to 8.58) and vomiting (aOR 2.54, 95% CI 1.33 to 4.84). CONCLUSION The significant risk factors associated with COVID-19 positivity and subsequent mortality in the Nigerian population are similar to those reported in studies from other countries and should guide clinical decisions for COVID-19 testing and specialist care referrals.
Collapse
Affiliation(s)
- Kelly Osezele Elimian
- Prevention, Programme and Knowledge Management, Nigeria Centre for Disease Control, Abuja, Nigeria
- Department of Microbiology, Faculty of Life Sciences, University of Benin, Benin City, Nigeria
| | - Chinwe Lucia Ochu
- Prevention, Programme and Knowledge Management, Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Blessing Ebhodaghe
- Prevention, Programme and Knowledge Management, Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Puja Myles
- Epidemiology and Public Health, University of Nottingham, Nottingham, UK
| | - Emily E Crawford
- Prevention, Programme and Knowledge Management, Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Ehimario Igumbor
- Prevention, Programme and Knowledge Management, Nigeria Centre for Disease Control, Abuja, Nigeria
- School of Public Health, University of the Western Cape, Bellville, South Africa
| | - Winifred Ukponu
- Center for Global Health Practice and Impact, Georgetown University, Abuja, Nigeria
| | - Adobola Olayinka
- WHO, Abuja, Nigeria
- Ahmadu Bello University, Zaria, Kaduna, Nigeria
| | - Olusola Aruna
- IHR Strengthening Project, Global Public Health, Public Health England, London, UK
- Public Health England, British High Commission Nigeria, Abuja, Nigeria
| | - Chioma Dan-Nwafor
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, FCT, Nigeria
| | | | - Oladipo Ogunbode
- Prevention, Programme and Knowledge Management, Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Rhoda Atteh
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, FCT, Nigeria
| | - William Nwachukwu
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, FCT, Nigeria
| | - Sudhir Venkatesan
- EMEA Data Science Hub, IQVIA, London, UK
- Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | - Rabi Usman
- Ministry of Health, Zamfara State, Zamfara, Nigeria
| | - Nwando Mba
- Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Olaolu Aderinola
- Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Nigeria
| | - Elsie Ilori
- Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, FCT, Nigeria
| | - John Oladejo
- Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Nigeria
| | | | - Chikwe Ihekweazu
- Office of the Director General, Nigeria Centre for Disease Control, Abuja, Nigeria
| |
Collapse
|